Related Experiment Video

Updated: Dec 4, 2025

Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice
10:47

Using Bioluminescent Imaging to Investigate Synergism Between Streptococcus pneumoniae and Influenza A Virus in Infant Mice

Published on: April 14, 2011

17.2K

Death Due to COVID-19 in an Infant with Combined Immunodeficiencies

Hamid Ahanchian1, Nasrin Moazzen1, Amin Saeidinia2

  • 1Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Endocrine, Metabolic & Immune Disorders Drug Targets
|October 22, 2020
PubMed

Insights

Severe combined immunodeficiencies (SCID) increase infants' vulnerability to fatal COVID-19. This case highlights the critical role of T cell immunity in combating viral infections like SARS-CoV-2.

Area of Science:

  • Immunology
  • Virology
  • Pediatrics

Background:

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses significant risks, particularly to adults with comorbidities.
  • Pediatric patients with inherited T cell defects are theoretically more susceptible to viral infections.

Observation:

  • This report details an infant diagnosed with severe combined immunodeficiencies (SCID).
  • The infant contracted and succumbed to COVID-19.

Findings:

  • The case demonstrates a fatal outcome of COVID-19 in an infant with SCID.
  • This underscores the critical role of T cell-mediated immunity in controlling SARS-CoV-2 infection.

Implications:

  • Understanding COVID-19 presentation in immunocompromised individuals is crucial.
  • This case emphasizes the need for tailored strategies for vulnerable pediatric populations.
Abstract

Keywords:
COVID-19Combined immunodeficiencybone marroow.cardiac injurydeathinfant

More Related Videos

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus11:18

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

13.2K
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

20.2K

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.7K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
606
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
576
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
81.7K
Vaccinations01:51

Vaccinations

Overview
49.9K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
831